MAR (Multiple Agglomerated Regression) is a novel Phase 2 clinical trial evaluating a polypill approach for Alzheimer's disease treatment. The trial investigates whether a combination therapy using multiple already-approved agents can provide disease-modifying benefits through complementary mechanisms.
| Parameter | Value |
|---|---|
| Trial ID | NCT06597058 |
| Phase | Phase 2 |
| Status | Recruiting |
| Enrollment | 103 patients |
| Intervention | MAR drug combination (multiple agents) |
| Control | Placebo |
| Duration | Not specified |
| Sponsor | Not specified |
| Start Date | Not specified |
The polypill approach in Alzheimer's disease is based on the hypothesis that combination therapy targeting multiple pathological pathways simultaneously may provide greater benefit than single-agent approaches. This strategy draws from successful polypill implementations in cardiovascular disease.
The MAR combination likely includes agents targeting:
The trial is actively recruiting patients. Results are anticipated to inform whether the polypill approach represents a viable strategy for AD treatment.